PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -40.0% | 163 | 0.0% | 0.00% | – |
| Q2 2023 | $5 | +25.0% | 163 | 0.0% | 0.00% | – |
| Q1 2023 | $4 | +100.0% | 163 | 0.0% | 0.00% | – |
| Q4 2022 | $2 | -99.8% | 163 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 163 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -75.0% | 163 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -33.3% | 163 | 0.0% | 0.00% | – |
| Q4 2021 | $6,000 | +100.0% | 163 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | -25.0% | 163 | +101.2% | 0.00% | – |
| Q2 2021 | $4,000 | +100.0% | 81 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 81 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -50.0% | 81 | -58.7% | 0.00% | – |
| Q3 2020 | $4,000 | +300.0% | 196 | +27.3% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 154 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 154 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | – | 154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |